HUMA Latest News, Press Relases and Analysis

All

Press Releases

17 hours ago - By: Zacks Investment Research

Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?

8 days ago - By: The Motley Fool

Humacyte (HUMA) Q3 2025 Earnings Call Transcript

16 days ago - By: Humacyte, Inc

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

22 days ago - By: Zacks Investment Research

Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views?

23 days ago - By: Humacyte, Inc

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

25 days ago - By: Benzinga

Insights Ahead: Humacyte's Quarterly Earnings

2 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

4 months ago - By: Benzinga

An Overview of Humacyte's Earnings

4 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

24 days ago - By: Zacks Investment Research - Mentions: TELA

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

24 days ago - By: Humacyte, Inc

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

a month ago - By: Humacyte, Inc

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

a month ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

2 months ago - By: ACCESS Newswire

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

2 months ago - By: Humacyte, Inc

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

2 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

3 months ago - By: Humacyte, Inc

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

3 months ago - By: Humacyte, Inc

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

4 months ago - By: Zacks Investment Research

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

4 months ago - By: Zacks Investment Research - Mentions: EDIT

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: The Motley Fool

Humacyte Posts Q2 Revenue Miss

4 months ago - By: Humacyte, Inc

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Zacks Investment Research

HUMACYTE INC (HUMA) Stock News

HUMA Latest News, Press Relases and Analysis

Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?

Humacyte (HUMA) Q3 2025 Earnings Call Transcript

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views?

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Insights Ahead: Humacyte's Quarterly Earnings

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

An Overview of Humacyte's Earnings

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte Posts Q2 Revenue Miss

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights